PRESS RELEASE For immediate release Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver. QUÉBEC, Quebec, February 12, 2026 – Devonian Health Group Inc....
Press Releases
DEVONIAN REPORTS POSITIVE RESULTS IN PULMONARY FIBROSIS STUDY
PRESS RELEASE For immediate release Positive results from the Bleomycin Pulmonary Fibrosis mouse model in vivo study attributing Thykamine™ with anti-fibrotic effects in lungs Compelling results compared to Pirfenidone, a drug used to treat idiopathic pulmonary...
Devonian appoints Dennis Turpin as chief financial officer and provides updates on stock options grant
QUÉBEC, Québec, February 2, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solutions to fibroinflammatory diseases, is pleased to announce that it has appointed...
Devonian announces share consolidation in further preparation for potential U.S. listing
QUÉBEC, Québec, January 20, 2026 – Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF) is pleased to announce that, in connection with an evaluation of an additional listing of the Company’s common shares (“Common Shares”) on a U.S....